Kai Yin

机构：Capital Medical University, Peking University, Beijing Jishuitan Hospital, Wuhan University, First Affiliated Hospital of Zhengzhou University · ORCID：0000-0001-8802-766X

发表论文 61 篇 · 总被引 967 次 · h-index 12

代表论文

• Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer (2022 · Frontiers in Immunology · 被引 133)
• PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma (2022 · Frontiers in Immunology · 被引 33)
• Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC (2024 · Cell Reports · 被引 24)
• Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases (2022 · BMC Medicine · 被引 12)
• The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study (2025 · Annals of Oncology · 被引 9)
• Genomic and immune characteristics of HER2 ‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy (2023 · Molecular Oncology · 被引 9)